EUVIMEDEUVIMED entdecken
Crossref

Serum sodium and chloride interplay and the effect of empagliflozin in heart failure: an EMPEROR-Pooled analysis

João Pedro Ferreira, Faiez Zannad, Gerasimos Filippatos, Pedro Marques, Francisco Vasques-Nóvoa, Javed Butler, Stefan D Anker, Milton Packer

Clinical Research in Cardiology · 05.11.2026

DOI: 10.1007/s00392-026-03047-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Research in Cardiology, online erschienen am 05.11.2026. Verfasst von João Pedro Ferreira und 7 weiteren Autor:innen. Beteiligte Einrichtung: RISE-Health, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Alameda Prof. Hernâni Monteiro, 4200-319, Porto, Portuga…. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: SGLT2 inhibitors promote changes in the kidney that influence water and electrolyte handling. Prior studies in heart failure (HF) suggested that SGLT2 inhibitors produce a slight increase in serum sodium over time, but little is known about their impact on serum chloride and the sodium-chloride interplay. AIMS: To study the serum sodium-chloride interdependence, their prognostic associations, and the impact of empagliflozin on their levels over time. METHODS: EMPEROR-Pooled data (N = 9718) was used to create four mutually exclusive sodium-chloride categories based on quintiles (Q) of variable values distribution at baseline: (1) Q1Na+/Q1Cl-; (2) Q1Na+/ ≥ Q2Cl-; 3) ≥ Q2Na+/Q1Cl-; and (4) ≥ Q2Na+/ ≥ Q2Cl-. Cox models were used to study the association of these categories with outcomes. Mixed models for repeated measures were used to study the impact of empagliflozin vs placebo on sodium and chloride levels over time. RESULTS: Mean serum sodium levels were 140.9 ± 3.0 mmol/L and chloride 100.9 ± 3.6 mmol/L. Patients with both Na+ 0.1. Compared to placebo, empagliflozin slightly increased Na+ and Cl- by + 0.1 mmol/L on average, particularly from week 32 onwards (P < 0.05), while reducing serum bicarbonate levels by -0.2 mmol/L on average (P < 0.05). CONCLUSION: In ambulatory HF, lower serum chloride levels were associated with poor outcomes independently of sodium, whereas lower sodium levels were associated with poor outcomes only in the presence of relatively low chloride. The beneficial effects of empagliflozin were not impacted by sodium or chloride.

Schlagwörter

Stichwörter der Autor:innen

ChlorideEmpagliflozinHeart failureSodium

Autor:innen und Institutionen

  • RISE-Health, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Alameda Prof. Hernâni Monteiro, 4200-319, Porto, Portugal. jpferreira@med.up.pt.
  • Inserm, Centre d'Investigations Cliniques, - Plurithématique 14-33, and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Université de Lorraine, Nancy, France. jpferreira@med.up.p…
  • Inserm, Centre d'Investigations Cliniques, - Plurithématique 14-33, and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Université de Lorraine, Nancy, France.
  • School of Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • RISE-Health, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Alameda Prof. Hernâni Monteiro, 4200-319, Porto, Portugal.
  • Baylor Scott and White Research Institute, Dallas, TX, USA.

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Ferreira, J. P., Zannad, F., Filippatos, G., Marques, P., Vasques-Nóvoa, F., Butler, J., Anker, S. D., & Packer, M. (2026). Serum sodium and chloride interplay and the effect of empagliflozin in heart failure: an EMPEROR-Pooled analysis. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-03047-6

Vancouver

Ferreira JP, Zannad F, Filippatos G, Marques P, Vasques-Nóvoa F, Butler J, et al. Serum sodium and chloride interplay and the effect of empagliflozin in heart failure: an EMPEROR-Pooled analysis. Clinical Research in Cardiology. 2026. doi:10.1007/s00392-026-03047-6

BibTeX
@article{Ferreira2026,
  author = {Ferreira, João Pedro and Zannad, Faiez and Filippatos, Gerasimos and Marques, Pedro and Vasques-Nóvoa, Francisco and Butler, Javed and Anker, Stefan D and Packer, Milton},
  title = {Serum sodium and chloride interplay and the effect of empagliflozin in heart failure: an EMPEROR-Pooled analysis},
  journal = {Clinical Research in Cardiology},
  year = {2026},
  doi = {10.1007/s00392-026-03047-6}
}
Kostenlos starten →